Lixte Biotechnology Holdings, Inc. (LIXT) — Financial statements
Income statement, balance sheet, and cash flow for Lixte Biotechnology Holdings, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.25↓64.9% | 0.73↓19.1% | 0.90↓33.4% | 1↓22.3% | 2 | |
| General & Administrative Expenses | 5↑70.5% | 3↓32.1% | 4↓15.5% | 5↓0.4% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 5↑70.5% | 3↓32.1% | 4↓15.5% | 5↓0.4% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 5↑43.0% | 4↓29.8% | 5↓19.3% | 6↓6.1% | 7 | |
| Total Costs & Expenses | 5↑43.0% | 4↓29.8% | 5↓19.3% | 6↓6.1% | 7 | |
| Operating Results | ||||||
| Operating Income | -5↓43.0% | -4↑29.8% | -5↑19.3% | -6↑6.1% | -7 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -6↓68.1% | -4↑29.6% | -5↑19.6% | -6↑6.2% | -7 | |
| EBIT | -6↓68.1% | -4↑29.6% | -5↑19.6% | -6↑6.2% | -7 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.00↓125.1% | 0.01↑462.5% | 0.00↓46.0% | 0.00↑134.2% | -0.01 | |
| Interest Income | 0.01↑4.8% | 0.01↑462.5% | 0.00↓88.8% | 0.01↑1688.3% | 0.00 | |
| Interest Expense | 0.01 | 0.00 | 0.00↓100.0% | 0.01↑19.7% | 0.01 | |
| Non-Operating Income | 0.89↑24592.2% | -0.00↑81.3% | -0.02↓148.6% | -0.01↓1556.4% | 0.00 | |
| Other Income / Expenses | -0.90↓6745.0% | -0.01↓510.9% | 0.00↑404.3% | -0.00↑86.7% | -0.01 | |
| Income Before Tax | -6↓67.6% | -4↑29.5% | -5↑19.4% | -6↑6.2% | -7 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -6↓67.6% | -4↑29.5% | -5↑19.4% | -6↑6.2% | -7 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -6↓67.6% | -4↑29.5% | -5↑19.4% | -6↑6.2% | -7 | |
| Bottom-Line Net Income | -6↓69.5% | -4↑29.5% | -5↑19.4% | -6↑6.2% | -7 | |
| EPS (Basic) | -1.26↑20.8% | -1.59↑40.2% | -2.66↑33.5% | -4.00↑20.0% | -5.00 | |
| EPS (Diluted) | -1.26↑20.8% | -1.59↑40.2% | -2.66↑33.5% | -4.00↑20.0% | -5.00 | |
| Weighted Average Shares | 48↑2052.4% | 2↑17.6% | 2↑20.9% | 2↑17.4% | 1 | |
| Weighted Average Diluted Shares | 48↑2052.4% | 2↑17.4% | 2↑21.1% | 2↑17.4% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.